Multiple Myeloma | Specialty

The OncLive Multiple Myeloma condition center page is a comprehensive resource for clinical news and expert insights on multiple myeloma and how to treat patients with monoclonal antibodies, proteasome inhibitors, bispecific T-cell engagers, immunomodulatory agents, CAR T-cell therapy, and more. This page features news articles, interviews in written and video format, and podcasts that focus on unmet needs, treatment advances, and ongoing research in multiple myeloma.

Ixazomib/Daratumumab Elicits Encouraging Response in Elderly Frail Patients With R/R Multiple Myeloma

June 5th 2022

Ixazomib plus daratumumab without dexamethasone showed a positive efficacy profile for elderly frail patients with relapsed/refractory multiple myeloma, according to results of the phase 2 IFM 2018-02 study.

Daratumumab Plus RVd Demonstrates Durable MRD Negativity in Multiple Myeloma

June 5th 2022

Daratumumab plus induction/consolidation lenalidomide, bortezomib, and dexamethasone elicited higher minimal residual disease-negativity rates vs the RVd combination alone in patients with transplant-eligible newly diagnosed multiple myeloma, including those in high-risk subgroups.

RVd Plus Transplant and Lenalidomide Maintenance Improves PFS in Newly Diagnosed Myeloma

June 5th 2022

The combination of lenalidomide (Revlimid), bortezomib, and dexamethasone (RVd) plus autologous stem cell transplant as initial therapy followed by lenalidomide maintenance demonstrated a significant improvement in progression-free survival vs RVd alone followed by lenalidomide maintenance in patients with newly diagnosed multiple myeloma.

OncLive Honors 13 Cancer Care Pioneers

June 2nd 2022

For the 10th consecutive year, OncLive® is honored to recognize oncology leaders whose innovations have contributed to immeasurable improvements in outcomes for countless patients.

Patient Scenario 2: A 57-Year-Old With Heavily Pretreated MM

June 2nd 2022

Moving on to the second clinical scenario of multiple myeloma, Luciano Costa, MD, details his care of a heavily pretreated patient.

MajesTEC-1: Teclistamab in Relapsed or Refractory Multiple Myeloma

June 2nd 2022

Expert perspectives on the MajesTEC-1 trial, a study of BCMA- and CD3-targeted agent teclistamab in relapsed/refractory multiple myeloma.

Quadruplets, Bispecific Antibodies, and CAR T-Cell Therapies Usher in Advances in Multiple Myeloma

May 27th 2022

Noopur Raje, MD, reviews the benefits of quadruplet regimens in the up-front and relapsed settings, treatment options for relapsed/refractory disease, and the possibilities for combinations to minimize toxicities in those who receive CAR T-cell or bispecific antibody therapies.

Triple-Class Refractory MM: Factors in Selecting Optimal Therapy

May 26th 2022

Shared insight on factors that help to determine optimal therapy for patients diagnosed with triple-class refractory multiple myeloma.

Patient Scenario 1: A 66-Year-Old With Triple-Class Refractory MM

May 26th 2022

Expert hematologist-oncologist Adriana Rossi, MD, shares a real-world patient scenario of triple-class refractory multiple myeloma managed with novel bispecific antibody therapy.

Selinexor Combo Approaches EU Approval for Refractory Multiple Myeloma

May 20th 2022

The European Medicines Agency’s Committee for Medicinal Products for Human Use has recommended the approval of selinexor in combination with bortezomib and low-dose dexamethasone for use in adult patients with multiple myeloma who have previously received 1 to 3 prior lines of treatment.

Trial Assessing CAR T-Cell Therapy ACLX-001 in Relapsed/Refractory Multiple Myeloma Begins

May 19th 2022

Investigators have initiated a phase 1 trial exploring ACLX-001, a novel CAR T-cell therapy using the ARC-SparX platform, in patients with relapsed/refractory multiple myeloma.

Isatuximab Combo Significantly Improves PFS in Relapsed Multiple Myeloma

May 16th 2022

The addition of isatuximab-irfc to carfilzomib and dexamethasone resulted in a significant improvement in progression-free survival vs carfilzomib plus dexamethasone alone in patients with relapsed or refractory multiple myeloma.

Teclistamab/Daratumumab Combo Delivers Promising ORR in Heavily Pretreated Relapsed/Refractory Myeloma

May 10th 2022

Paula Rodriguez-Otero, MD, PhD, discusses the rationale, design, and findings of the phase 1b TRIMM-2 trial assessing subcutaneous teclistamab in combination with daratumumab for the treatment of patients with relapsed/refractory multiple myeloma.

FDA-Approved CAR T-Cell Therapies Illuminate Advances in Multiple Myeloma

May 9th 2022

Noopur S. Raje, MD, discussed the presentation she gave at the 26th Annual International Congress on Hematologic Malignancies® on the CAR T-cell therapy product bb21217, other exciting myeloma treatments that were presented at ASH, and the need for increased treatment accessibility.

Cilta-Cel Induces Impressive ORR in Relapsed/Refractory Multiple Myeloma

May 3rd 2022

Thomas Martin, MD, discusses updates from the CARTITUDE-1 trial, as well as the future of CARs and bispecific T cell engagers in multiple myeloma.

Four Baseline Characteristics Predict CR/sCR in Multiple Myeloma

April 25th 2022

Investigators have identified immunoglobulin G heavy chain, soluble B-cell maturation agent, prothrombin time and international normalized ratio, and high vector copy number in drug product as predictors for response in patients with multiple myeloma.

Single Infusion of Cilta-Cel Elicits Early Responses in Myeloma

April 25th 2022

Ciltacabtagene autoleucel generated deep responses and demonstrated manageable safety in patients with progressive multiple myeloma who were refractory to lenalidomide.

Dr. Lin on Treatment Updates in CAR T-Cell Therapy in Myeloma

April 21st 2022

Yi Lin, MD, PhD, discusses treatment updates in CAR T-cell therapy in multiple myeloma.

Dr. Larocca on Recent Advancements in R/R Multiple Myeloma

April 6th 2022

Alessandra Larocca, MD, PhD, discusses recent advancements in relapsed/refractory multiple myeloma.

Precursor Conditions Unlock Potential for Early Interventions in Multiple Myeloma

March 29th 2022

Data presented at the ASH Annual Meeting and Exposition underscored the growing focus on improving screening, advancing methods of detection, and improving our understanding of the genomic, genetic, and epigenetic factors that govern progression and therapeutic resistance in multiple myeloma.